Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00126542 · ClinicalTrials.gov registry record · Phase 2

Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

A Phase 2 study of Fallopian Tube Cancer and Primary Peritoneal Cavity Cancer, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 2
Development phase
35
Enrollment target
1
Study location

NCT00126542 is a Phase 2 study of Fallopian Tube Cancer and Primary Peritoneal Cavity Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 35 participants, below the 255-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00126542, a Phase 2 study of Fallopian Tube Cancer and Primary Peritoneal Cavity Cancer, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 2
Development phase
35 participants
Enrollment target
1
Study location

Study Summary

This phase II trial is studying how well giving bevacizumab together with erlotinib works in treating patients with recurrent or metastatic ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving bevacizumab together with erlotinib may kill more tumor cells.

Conditions Studied

Fallopian Tube Cancer Primary Peritoneal Cavity Cancer Recurrent Ovarian Epithelial Cancer Stage IV Ovarian Epithelial Cancer

Interventions

  • OTHER laboratory biomarker analysis
  • BIOLOGICAL bevacizumab
  • DRUG erlotinib hydrochloride

Study Locations (1)

Illinois

  • University of Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2005-04
Est. Completion 2010-04
Phase Phase 2

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00126542

The ClinicalTrials.gov registry entry for NCT00126542 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 255-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (86% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Fallopian Tube Cancer appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.

NCT00126542 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT00126542 about?

NCT00126542 is a clinical study titled "Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer". This phase II trial is studying how well giving bevacizumab together with erlotinib works in treating patients with recurrent or metastatic ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. S...

What is the current status of trial NCT00126542?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2005-04. Estimated completion is 2010-04.

What conditions does trial NCT00126542 study?

This clinical trial studies the following conditions: Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer.

What interventions are being tested in trial NCT00126542?

The interventions under investigation include: laboratory biomarker analysis (OTHER), bevacizumab (BIOLOGICAL), erlotinib hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00126542?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00126542 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Fallopian Tube Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Fallopian Tube Cancer

All registered trials for this condition

Primary Peritoneal Cavity Cancer

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.